Myriad Genetics Inc (MYGN) stock
MYGNNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 8/3070% below fair value
$5.54−0.03 (-0.54%)
Close on Nov 17, 2026Market cap $529.90MP/E –Yield –
Myriad Genetics ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Myriad Genetics's ebitda for the twelve months ending Jun 30, 2026 was -$48.40M. For fiscal 2025 it was -$333.50M. The highest annual figure on record is $288.20M in fiscal 2014.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$333.50M | – |
| FY2024 | Dec 31, 2024 | -$62.30M | – |
| FY2023 | Dec 31, 2023 | -$195.50M | – |
| FY2022 | Dec 31, 2022 | -$87.90M | – |
| FY2020 | Jun 30, 2020 | -$159.70M | -298.1% |
| FY2019 | Jun 30, 2019 | $80.60M | -54.3% |
| FY2018 | Jun 30, 2018 | $176.30M | +91.0% |
| FY2017 | Jun 30, 2017 | $92.30M | -48.8% |
| FY2016 | Jun 30, 2016 | $180.20M | +13.6% |
| FY2015 | Jun 30, 2015 | $158.60M | -45.0% |
| FY2014 | Jun 30, 2014 | $288.20M | +21.7% |
| FY2013 | Jun 30, 2013 | $236.90M | +25.1% |
| FY2012 | Jun 30, 2012 | $189.39M | +14.8% |
| FY2011 | Jun 30, 2011 | $165.00M | +16.1% |
| FY2010 | Jun 30, 2010 | $142.16M | +4.6% |
| FY2009 | Jun 30, 2009 | $135.91M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026CQ2 2026 | Jun 30, 2026 | -$26.40M | – |
| Q1 FY2026CQ1 2026 | Mar 31, 2026 | -$18.20M | – |
| Q4 FY2025CQ4 2025 | Dec 31, 2025 | $6.90M | – |
| Q3 FY2025CQ3 2025 | Sep 30, 2025 | -$10.70M | – |
| Q2 FY2025CQ2 2025 | Jun 30, 2025 | -$315.10M | – |
| Q1 FY2025CQ1 2025 | Mar 31, 2025 | -$14.60M | – |
| Q4 FY2024CQ4 2024 | Dec 31, 2024 | -$24.20M | – |
| Q3 FY2024CQ3 2024 | Sep 30, 2024 | -$4.40M | – |
| Q2 FY2024CQ2 2024 | Jun 30, 2024 | -$21.40M | – |
| Q1 FY2024CQ1 2024 | Mar 31, 2024 | -$12.20M | – |
| Q4 FY2023CQ4 2023 | Dec 31, 2023 | -$16.30M | – |
| Q3 FY2023CQ3 2023 | Sep 30, 2023 | -$46.00M | – |
| Q2 FY2023CQ2 2023 | Jun 30, 2023 | -$100.40M | – |
| Q1 FY2023CQ1 2023 | Mar 31, 2023 | -$32.80M | – |
| Q4 FY2022CQ4 2022 | Dec 31, 2022 | -$38.50M | – |
| Q3 FY2022CQ3 2022 | Sep 30, 2022 | -$31.90M | – |
| Q2 FY2022CQ2 2022 | Jun 30, 2022 | -$4.90M | -152.1% |
| Q1 FY2022CQ1 2022 | Mar 31, 2022 | -$12.60M | – |
| Q4 FY2020CQ2 2020 | Jun 30, 2020 | -$50.60M | -495.3% |
| Q3 FY2020CQ1 2020 | Mar 31, 2020 | -$115.80M | -578.5% |
| Q2 FY2020CQ4 2019 | Dec 31, 2019 | $9.40M | -61.0% |
| Q1 FY2020CQ3 2019 | Sep 30, 2019 | -$2.70M | -113.8% |
| Q4 FY2019CQ2 2019 | Jun 30, 2019 | $12.80M | -61.1% |
| Q3 FY2019CQ1 2019 | Mar 31, 2019 | $24.20M | -9.4% |
| Q2 FY2019CQ4 2018 | Dec 31, 2018 | $24.10M | +24.2% |
| Q1 FY2019CQ3 2018 | Sep 30, 2018 | $19.50M | -79.9% |
| Q4 FY2018CQ2 2018 | Jun 30, 2018 | $32.90M | +2.2% |
| Q3 FY2018CQ1 2018 | Mar 31, 2018 | $26.70M | +45.1% |
| Q2 FY2018CQ4 2017 | Dec 31, 2017 | $19.40M | -35.5% |
| Q1 FY2018CQ3 2017 | Sep 30, 2017 | $97.20M | +496.3% |
| Q4 FY2017CQ2 2017 | Jun 30, 2017 | $32.20M | +11.0% |
| Q3 FY2017CQ1 2017 | Mar 31, 2017 | $18.40M | -62.6% |
| Q2 FY2017CQ4 2016 | Dec 31, 2016 | $30.10M | -42.1% |
| Q1 FY2017CQ3 2016 | Sep 30, 2016 | $16.30M | -67.5% |
| Q4 FY2016CQ2 2016 | Jun 30, 2016 | $29.00M | -31.3% |
| Q3 FY2016CQ1 2016 | Mar 31, 2016 | $49.20M | +16.9% |
| Q2 FY2016CQ4 2015 | Dec 31, 2015 | $52.00M | – |
| Q1 FY2016CQ3 2015 | Sep 30, 2015 | $50.10M | – |
| Q4 FY2015CQ2 2015 | Jun 30, 2015 | $42.20M | – |
| Q3 FY2015CQ1 2015 | Mar 31, 2015 | $42.10M | – |
See a number that looks wrong?